Royalty Pharma plc

RPRX Nasdaq SEC CIK 1802768
Follow Royalty Pharma Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $690.1M +13.3% vs same quarter last year
Net income $144.7M −49.1% vs same quarter last year
EPS, diluted $0.32 −51.5% vs same quarter last year
Operating cash flow $686.1M −2.4% vs same quarter last year
Revenue by quarter
$593.6M
$568.2M
$578.7M
$609.3M
$622M
$630.6M
$674.1M
$690.1M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income9 fiscal years
  • Revenue
  • Net income
$0$1B$2B$3BFY17FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearRevenueNet income
FY25$2.4B$770.9M
FY24$2.3B$859M
FY23$2.4B$1.1B
FY22$2.2B$42.8M
FY21$2.3B$619.7M
FY20$2.1B$975M
FY19$1.8B$2.3B
FY18$1.8B$1.4B
FY17--
MarginsShare of revenue
  • Operating margin
  • Net margin
0%50%100%150%FY17FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearOperating marginNet margin
FY2565.6%32.4%
FY2457.1%37.9%
FY2363.4%48.2%
FY2213.7%1.9%
FY2162.5%27.1%
FY2075.2%45.9%
FY19144.6%129.4%
FY1876%76.8%
FY17--
Returned to shareholdersDividends paid and shares bought back
$0$500M$1B$1.5BFY17FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearBuybacks
FY25$1.2B
FY24$229.7M
FY23$304.8M
FY22$0
FY21$0
FY20$0
FY19$4.3M
FY18$0
FY17-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Royalty Pharma
  • Healthcare median
−100%0%100%200%FY17FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearRoyalty PharmaHealthcare median
FY2532.4%−30.6%
FY2437.9%−47%
FY2348.2%−58%
FY221.9%−80.4%
FY2127.1%−71.9%
FY2045.9%−62.2%
FY19129.4%−46.3%
FY1876.8%−49.6%
FY17-−45.9%